Related references
Note: Only part of the references are listed.Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens
Michele Senni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
Jordan B. King et al.
JACC-HEART FAILURE (2016)
The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications
Gordon W. Moe et al.
CANADIAN JOURNAL OF CARDIOLOGY (2015)
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Akshay S. Desai et al.
EUROPEAN HEART JOURNAL (2015)
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Pardeep S. Jhund et al.
EUROPEAN HEART JOURNAL (2015)
Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores
Joanne Simpson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Making Sense of Statistics in Clinical Trial Reports Part 1 of a 4-Part Series on Statistics for Clinical Trials
Stuart J. Pocock et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
Milton Packer et al.
CIRCULATION (2015)
Effects of Neutral Endopeptidase (Neprilysin) Inhibition on the Response to Other Vasoactive Peptides in Small Human Resistance Arteries: Studies with Thiorphan and Omapatrilat
Jonathan R. Dalzell et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Natriuretic peptide-guided heart failure management
Richard Troughton et al.
EUROPEAN HEART JOURNAL (2014)
Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study
Helle Bosselmann et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
Laxminarayan G. Hegde et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Effect of Nesiritide in Patients with Acute Decompensated Heart Failure
C. M. O'Connor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003 A Population Study of 5.1 Million People
Pardeep S. Jhund et al.
CIRCULATION (2009)
Prognostic Value of Biomarkers in Heart Failure Application of Novel Methods in the Community
Shannon M. Dunlay et al.
CIRCULATION-HEART FAILURE (2009)
Effects of Carperitide on the Long-Term Prognosis of Patients With Acute Decompensated Chronic Heart Failure-The PROTECT Multicenter Randomized Controlled Study-
Noritake Hata et al.
CIRCULATION JOURNAL (2008)
Natriureettic peptides
Lori B. Daniels et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure
MT Rademaker et al.
CLINICAL SCIENCE (2004)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
JN Cohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
